[1] MOLITCH M E,DEFRONZO R A,FRANZ M J,et al.Nephropathy in diabetes[J].Diabetes Care,2004,27(S1):S79-S83.
[2] National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD:2012 Update[J].Am J Kidney Dis,2012,60(5):850-886.
[3] CARAMORI M L,MAUER M. Diabetes and nephropathy[J],Curr Opin Nephrol Hypertens,2003,12(3):273-282.
[4] REMUZZI G,SCHIEPPATI A,RUGGENENTI P. Clinical practice. Nephropathy in patients with type 2 diabetes[J].N Engl J Med,2002,346(15):1145-1151.
[5] WOLF G,RITZ E. Diabetic nephropathy in type 2 diabetes prevention and patient management[J].J Am Soc Nephrol,2003,14(5):1396-1405.
[6] NAVARRO-GONZALEZ J F,MORA-FERNANDEZ C. The role of inflammatory cytokines in diabetic nephropathy[J].J Am Soc Nephrol,2008,19(3):433-442.
[7] RIVERO A,MORA C,MUROS M,et al. Pathogenic perspectives for the role of inflammation in diabetic nephropathy[J].Clin Sci(Lond),2009,116(6):479-492.
[8] ABBAS A K,MURPHY K M,SHER A. Functional diversity of helper T lymphocytes[J].Nature,1996,383(6603):787-793.
[9] MOSMANN T R,SAD S. The expanding universe of T-cell subsets:Th1,Th2 and more[J].Immunol Today,1996,17(3):138-146.
[10] MIOSSEC P,KORN T,KUCHROO V K. Interleukin-17 and type 17 helper T cells[J].N Engl J Med,2009,361(9):888-898.
[11] KING C,TANGYE S G,MACKAY C R. T follicular helper(TFH) cells in normal and dysregulated immune responses[J].Annu Rev Immunol,2008,26:741-766.
[12] CROTTY S. Follicular helper CD4 T cells(TFH)[J].Annu Rev Immunol,2011,29:621-663.
[13] SHALEV I,SCHMELZLE M,ROBSON S C,et al. Making sense of regulatory T cell suppressive function[J].Semin Immunol,2011,23(4):282-292.
[14] SHI J H,SUN S C. Tumor necrosis factor receptor-associated factor regulation of nuclear factor κB and mitogen-activated protein kinase pathways[J].Front Immunol,2018,9:1849.
[15] LAMPROPOULOUA I T,STANGOUA M,SARAFIDISA P,et al. TNF-α pathway and T-cell immunity are activated early during thedevelopment of diabetic nephropathy in Type Ⅱ Diabetes Mellitus[J].Clin Immuno,2020,215:108423.
[16] FERNANDEZ-REAL M,VENDRELL J,GARCIA I,et al. Structural damage in diabetic nephropathy is associated with TNF-α system activity[J].Acta Diabetol,2012,49(4):301-305.
[17] ZHANG H,ZHANG R,CHEN J,et al. High mobility group Box1 inhibitor glycyrrhizic acid attenuates kidney injury in Streptozotocin-induced diabetic rats[J].Kidney Blood Press Res,2017,42(5):894-904.
[18] NAVARRO-GONZÁLEZ J F,MORA-FERNÁNDEZ C,MUROS DE F M,et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy[J].Nat Rev Nephrol,2011,7(6):327-340.
[19] MURAKOSHI M,GOHDA T,SUZUKI Y. Circulating tumor necrosis factor receptors:a potential biomarker for the progression of diabetic kidney disease[J]. Int J Mol Sci,2020,21(6):1957.
[20] NAVARRO-GONZÁLEZ J F,MORA-FERNÁNDEZ C,GOMEZ M,et al. Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-alpha and interleukin-6 in type 2 diabetic patients[J].Nephrol Dial Transplant,2008,23(3):919-926.
[21] MOON J Y,JEONG K H,LEE T W,et al. Aberrant recruitment and activation of T cells in diabetic nephropathy[J].Am J Nephrol,2012,35(2):164-174.
[22] MORITA R,SCHMITT N,BENTEBIBEL S E,et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion[J].Immunity,2011,34(1):108-121.
[23] BEKRIS L M,KAVANAGH T J,LERNMARK A. Targeting type 1 diabetes before and at the clinical onset of disease[J].Endocr Metab Immune Disord Drug Targets,2006,6(1):103-124.
[24] MAHMOUD F,AL-OZAIRI E. Inflammatory cytokines and the risk of cardiovascular complications in type 2 diabetes[J].Dis Markers,2013,35(4):235-241.
[25] YANG T T,SONG S J,XUE H B,et al. Regulatory T cells in the pathogenesis of type 2 diabetes mellitus retinopathy by mir-155[J].Eur Rev Med Pharmacol Sci,2015,19(11):2010-2015.
[26] FABRIZI M,MARCHETTI V,MAVILIO M,et al. IL-21 is a major negative regulator of irf4-dependent lipolysis affecting tregs in adipose tissue and systemic insulin sensitivity[J].Diabetes,2014,63(6):2086-2096.
[27] ELLER K,KIRSCH A,WOLF A M,et al.Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy[J].Diabetes,2011,60(11):2954-2962.
[28] ZHANG C P,XIAO C C,WANG P,et al.The alteration of Th1/Th2/Th17/Treg paradigm in patients with type 2 diabetes mellitus:relationship with diabetic nephropathy[J].Hum Immunol,2014,75(4):289-296.
[29] ABOUZEID S,SHERIF N.Role of alteration in Treg/Th17 cells' balance in nephropathic patients with type 2 diabetes mellitus[J].Electron Physician,2015,7(8):1613-1618.
[30] LAURENT C,FAZILLEAU N,BROUSSET P. A novel subset of T-helper cells:follicular T-helper cells and their markers[J].Haematologica,2010,95(3):356-358.
[31] LINTERMAN M A,VINUESA C G. Signals that influence T follicular helper cell differentiation and function[J].Semin Immunopathol,2010,32(2):183-196.
[32] ZHANG N,TAI J D,QU Z H,et al. Increased CD4+CXCR5+T follicular helper cells in diabetic nephropathy[J].Autoimmunity,2016,49(6):405-413.
[33] GOLDWITH A,BURKARD M,OLKE M,et al. Podocytes are nonhematopoietic professional antigen-presenting cells[J].J Am Soc Nephrol,2013,24(6):906-916.
[34] YE L L,WEI X S,ZHANG M,et al. The significance of tumor necrosis factor receptor type Ⅱ in CD8+Regulatory T Cells and CD8+effector T Cells[J].Front Immunol,2018,9:583.
[35] SO T,NAGASHIMA H,ISHII N.TNF receptor-associated factor(TRAF) signaling network in CD4(+) T-lymphocytes[J].Tohoku J Exp Med,2015,236(2):139-154.
[36] CHOW F,OZOLS E,NIKOLIC-PATERSON D J,et al. Macrophages in mouse type 2 diabetic nephropathy:correlation with diabetic state and progressive renal injury[J].Kidney Int,2004,65(1):116-128.
[37] TESCH G H.Macrophages and diabetic nephropathy[J].Semin Nephrol,2010,30(3):290-301.
[38] WANG Y P,HARRIS D C H. Macrophages in renal disease[J].J Am Soc Nephrol,2011,22(1):21-27.
[39] CHOW F Y,NIKOLIC-PATERSON D J,OZOLS E,et al. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice[J].Kidney Int,2006,69(1):73-80.
[40] SATRIANO J A,HORA K,SHAN Z,et al.Regulation of monocyte chemoattractant protein-1 and macrophage colony-stimulating factor-1 by IFN-γ,tumor necrosis factor-α,IgG aggregates,and cAMP in mouse mesangial cells[J].J Immunol,1993,150(5):1971-1978.
[41] TIEMESSEN M M,JAGGER A L,EVANS H G,et al.CD4+CD25+Foxp3+regulatory T cells induce alternative activation of human monocytes/macrophages[J].Proc Natl Acad Sci U S A,2007,104(49):19446-19451.
[42] LIU G,MA H,QIU L,et al. Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+T cells in mice[J].Immunol Cell Biol,2011,89(1):130-142.
[43] WESTCOTT D J,DELPROPOSTO J B,Geletka L M,et al. MGL1 promotes adipose tissue inflammation and insulin resistance by regulating 7/4hi monocytes in obesity[J].J Exp Med,2009,206(13):3143-3156.
[44] WUEEST S,RAPOLD R A,SCHUMANN D M,et al. Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice[J].J Clin Invest,2010,120(1):191-202.
[45] CHIU Y L,TSAI W C,HUNG R W,et al.Emergence of T cell immunosenescence in diabetic chronic kidney disease[J].Immun Ageing,2020,17:31. |
